The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 4, 2014, Pages 319-326

  Zhou, Yi ^a   Slack, Rebecca ^a   Jorgensen, Jeffrey L ^a   Wang, Sa A ^a   Rondon, Gabriela ^a   De Lima, Marcos ^a   Shpall, Elizabeth ^a   Popat, Uday ^a   Ciurea, Stefan ^a   Alousi, Amin ^a   Qazilbash, Muzaffar ^a   Hosing, Chitra ^a   O'Brien, Susan ^a   Thomas, Deborah ^a   Kantarjian, Hagop ^a   Medeiros, L Jeffrey ^a   Champlin, Richard E ^a   Kebriaei, Partow ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Flow cytometry; Monitoring; Predictor; Prognosis; Relapse

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; DISEASE ASSOCIATION; EARLY INTERVENTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; ADOLESCENT; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MORTALITY; NEOPLASM, RESIDUAL; PATHOLOGY; POSTOPERATIVE PERIOD; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREOPERATIVE PERIOD; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POSTOPERATIVE PERIOD; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREOPERATIVE PERIOD; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904709033     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.01.002     Document Type: Article

References (49)

1. R. Dinsmore, D. Kirkpatrick, and N. Flomenberg et al. Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia Blood 62 1983 381 388
2. A.H. Goldstone, S.M. Richards, and H.M. Lazarus et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood 111 2008 1827 1833
3. A.K. Fielding, J.M. Rowe, and S.M. Richards et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993 Blood 113 2009 4489 4496
4. A.J. Barrett, M.M. Horowitz, and R.C. Ash et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 79 1992 3067 3070
5. M. Eapen, E. Raetz, and M.J. Zhang et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research Blood 107 2006 4961 4967
6. C. Uderzo, M.G. Valsecchi, and A. Bacigalupo et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association J Clin Oncol 13 1995 352 358
7. M. Duval, J.P. Klein, and W. He et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure J Clin Oncol 28 2010 3730 3738
8. J.R. Wingard, S. Piantadosi, and G.W. Santos et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia J Clin Oncol 8 1990 820 830
9. S. Malempati, P.S. Gaynon, H. Sather, M.K. La, and L.C. Stork Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952 J Clin Oncol 25 2007 5800 5807
10. A.J. Barrett, M.M. Horowitz, and R.P. Gale et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival Blood 74 1989 862 871
11. A.E. Woolfrey, C. Anasetti, and B. Storer et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children Blood 99 2002 2002 2008
12. A. Attarbaschi, G. Mann, and R. Panzer-Grumayer et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials J Clin Oncol 26 2008 3046 3050
13. G. Basso, M. Veltroni, and M.G. Valsecchi et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow J Clin Oncol 27 2009 5168 5174
14. P. Stow, L. Key, and X. Chen et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia Blood 115 2010 4657 4663
15. V. Conter, C.R. Bartram, and M.G. Valsecchi et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood 115 2010 3206 3214
16. M.J. Borowitz, M. Devidas, and S.P. Hunger et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood 111 2008 5477 5485
17. J. Zhou, M.A. Goldwasser, and A. Li et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood 110 2007 1607 1611
18. T. Raff, N. Gokbuget, and S. Luschen et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials Blood 109 2007 910 915
19. M. Bruggemann, T. Raff, and T. Flohr et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia Blood 107 2006 1116 1123
20. E.R. Panzer-Grumayer, M. Schneider, S. Panzer, K. Fasching, and H. Gadner Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia Blood 95 2000 790 794
21. R. Bassan, O. Spinelli, and E. Oldani et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood 113 2009 4153 4162
22. F.Y. Mortuza, M. Papaioannou, and I.M. Moreira et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia J Clin Oncol 20 2002 1094 1104
23. B. Patel, L. Rai, and G. Buck et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 Br J Haematol 148 2010 80 89
24. N. Goulden, P. Bader, and V. Van Der Velden et al. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia Br J Haematol 122 2003 24 29
25. P. Bader, H. Kreyenberg, and G.H. Henze et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group J Clin Oncol 27 2009 377 384
26. C.J. Knechtli, N.J. Goulden, and J.P. Hancock et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia Blood 92 1998 4072 4079
27. O. Krejci, V.H. van der Velden, and P. Bader et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group Bone Marrow Transplant 32 2003 849 851
28. P. Bader, J. Hancock, and H. Kreyenberg et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL Leukemia 16 2002 1668 1672
29. O. Spinelli, B. Peruta, and M. Tosi et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia Haematologica 92 2007 612 618
30. M. Uzunel, M. Jaksch, J. Mattsson, and O. Ringden Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia Br J Haematol 122 2003 788 794
31. X.S. Zhao, Y.R. Liu, and H.H. Zhu et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation Ann Hematol 91 2011 183 192
32. S. Giralt, K. Ballen, and D. Rizzo et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research Biol Blood Marrow Transplant 15 2009 367 369
33. H.M. Vriesendorp, H. Chu, T.G. Ochran, P.C. Besa, and R.E. Champlin Radiobiology of total body radiation Bone Marrow Transplant 14 suppl 4 1994 S4 S8
34. R. Gopal, C.S. Ha, and S.L. Tucker et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity Cancer 92 2001 1949 1958
35. P. Kebriaei, R.M. Saliba, and C. Ma et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia Bone Marrow Transplant 38 2006 203 209
36. P. Kebriaei, T. Madden, and X. Wang et al. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL Bone Marrow Transplant 48 2013 26 31
37. P. Kebriaei, R. Basset, and C. Ledesma et al. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation Biol Blood Marrow Transplant 18 2012 1819 1826
38. F. Ravandi, J. Jorgensen, and D.A. Thomas et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome -positive ALL treated with tyrosine kinase inhibitors plus chemotherapy Blood 122 2013 1214 1221
39. J. Cortes, M. Talpaz, and S. O'Brien et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate Clin Cancer Res 11 2005 3425 3432
40. D. Przepiorka, D. Weisdorf, and P. Martin et al. 1994 Consensus Conference on Acute GVHD Grading Bone Marrow Transplant 15 1995 825 828
41. K.M. Sullivan, H.M. Shulman, and R. Storb et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression Blood 57 1981 267 276
42. Mehta C, Patel N. StatXact4 for Windows. 2000:605-610. CYTEL Software Corporation, Cambridge, MA.
43. Mehta C, Patel N. StatXact4 for Windows. 2000:384-388. CYTEL Software Corporation, Cambridge, MA.
44. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
45. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187 220
46. W. Nelson Theory and applications of hazard plotting for censored failure data Technometrics 14 1972 945 966
47. O.O. Aalen Nonparametric inference for a family of counting processes Ann Stat 6 1978 701 726
48. W. Leung, C.H. Pui, and E. Coustan-Smith et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia Blood 120 2012 468 472
49. V.H. van der Velden, S.A. Joosten, and M.J. Willemse et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia Leukemia 15 2001 1485 1487